In the last five years, mutations of the mitochondrial DNA (mDNA) were identified in several neuro-ophthalmological diseases. However, the detailed molecular events associated with the pathology of these untreatable disorders are poorly understood. The first goal of the present application is to study the molecular pathogenesis of five different mDNA mutations recently identified in patients with mitochondrial disease. Four of these pathogenic mutations are point mutations in mitochondrial tRNA genes (tRNA for Leu, Asn, Pro, and Glu) while the fifth is a 260 bp duplication of the mtDNA regulatory region. These studies will be performed in trans-mitochondrial cybrids cell lines, generated by the fusion of an established mtDNA-less cells (termed p o cells) with enucleated patient's cells. The trans-mitochondrial cybrid system has several advantages over primary cell lines for the study of mtDNA mutations, the most important being their immortal phenotype. Trans-mitochondrial cybrids containing 100% mutated, 100% wild-type, and different percentages of both mtDNAs, will be studied for organelle protein synthesis, mitochondrial transcription, mtDNA replication, RNA processing, and tRNA aminoacylation. Characterized trans-mitochondrial cell lines will also be used as model systems to test the feasibility of expression of mitochondrial genes in the nucleus, the second major goal of this application. To express mitochondrial genes in the nucleus, they have to be extensively modified by site-directed mutagenesis. This is necessary in order to adjust the mitochondrial genetic code to the universal genetic code. Moreover, re-coded genes will need a mitochondrial targeting leader peptide to reach their functional location. Re-engineered genes will be transfected into the nucleus of cultured cells, and their expression, as well as the sub- cellular targeting and functional assembly of their protein products monitored. The knowledge accumulated by the studies described above should help set the stage for future gene replacement therapies for mitochondrial disorders.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY010804-03
Application #
2019953
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1994-12-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33146
Arguello, Tania; Köhrer, Caroline; RajBhandary, Uttam L et al. (2018) Mitochondrial methionyl N-formylation affects steady-state levels of oxidative phosphorylation complexes and their organization into supercomplexes. J Biol Chem 293:15021-15032
Nissanka, Nadee; Moraes, Carlos T (2018) Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. FEBS Lett 592:728-742
Pinto, Milena; Nissanka, Nadee; Moraes, Carlos T (2018) Lack of Parkin Anticipates the Phenotype and Affects Mitochondrial Morphology and mtDNA Levels in a Mouse Model of Parkinson's Disease. J Neurosci 38:1042-1053
Peralta, Susana; Goffart, Steffi; Williams, Sion L et al. (2018) ATAD3 controls mitochondrial cristae structure in mouse muscle, influencing mtDNA replication and cholesterol levels. J Cell Sci 131:
Garcia, Sofia; Nissanka, Nadee; Mareco, Edson A et al. (2018) Overexpression of PGC-1? in aging muscle enhances a subset of young-like molecular patterns. Aging Cell 17:
Madsen, Pernille M; Pinto, Milena; Patel, Shreyans et al. (2017) Mitochondrial DNA Double-Strand Breaks in Oligodendrocytes Cause Demyelination, Axonal Injury, and CNS Inflammation. J Neurosci 37:10185-10199
Pinto, Milena; Pickrell, Alicia M; Wang, Xiao et al. (2017) Transient mitochondrial DNA double strand breaks in mice cause accelerated aging phenotypes in a ROS-dependent but p53/p21-independent manner. Cell Death Differ 24:288-299
Tengan, Celia H; Moraes, Carlos T (2017) NO control of mitochondrial function in normal and transformed cells. Biochim Biophys Acta Bioenerg 1858:573-581
Pinto, Milena; Nissanka, Nadee; Peralta, Susana et al. (2016) Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation. Mol Neurodegener 11:25
Luo, Xueting; Ribeiro, Marcio; Bray, Eric R et al. (2016) Enhanced Transcriptional Activity and Mitochondrial Localization of STAT3 Co-induce Axon Regrowth in the Adult Central Nervous System. Cell Rep 15:398-410

Showing the most recent 10 out of 88 publications